https://www.opko.com/investors/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/opko/files/theme/images/logo-sm.png /investors Equisolve Investor Relations Suite https://www.opko.com/investors/news-events/press-releases/detail/555/opko-health-reports-third-quarter-2026-business-highlights-and-financial-results Wed, 04 Nov 26 16:23:00 -0500 https://www.opko.com/investors/news-events/press-releases/detail/555/opko-health-reports-third-quarter-2026-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/554/opko-health-to-report-third-quarter-2026-financial-results-on-november-4-2026 Wed, 28 Oct 26 08:52:00 -0400 https://www.opko.com/investors/news-events/press-releases/detail/554/opko-health-to-report-third-quarter-2026-financial-results-on-november-4-2026 https://www.opko.com/investors/news-events/press-releases/detail/553/opko-healths-opko-biologics-doses-first-participant-in-phase-12a-trial-of-opk-8801001-for-acromegaly Tue, 27 Oct 26 08:00:00 -0400 https://www.opko.com/investors/news-events/press-releases/detail/553/opko-healths-opko-biologics-doses-first-participant-in-phase-12a-trial-of-opk-8801001-for-acromegaly https://www.opko.com/investors/news-events/press-releases/detail/552/labcorp-enters-into-agreement-with-opko-health-to-acquire-select-assets-of-bioreference-health Thu, 15 Oct 26 07:30:00 -0400 https://www.opko.com/investors/news-events/press-releases/detail/552/labcorp-enters-into-agreement-with-opko-health-to-acquire-select-assets-of-bioreference-health https://www.opko.com/investors/news-events/press-releases/detail/551/opko-health-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference Tue, 08 Sep 26 13:55:00 -0400 https://www.opko.com/investors/news-events/press-releases/detail/551/opko-health-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/550/opko-health-expands-strategic-relationship-with-healthcare-royalty-through-125-million-notes-issuance-secured-by-mazdutide-royalty-interests Thu, 13 Aug 26 09:15:00 -0400 https://www.opko.com/investors/news-events/press-releases/detail/550/opko-health-expands-strategic-relationship-with-healthcare-royalty-through-125-million-notes-issuance-secured-by-mazdutide-royalty-interests https://www.opko.com/investors/news-events/press-releases/detail/549/opko-health-reports-second-quarter-2026-business-highlights-and-financial-results Mon, 27 Jul 26 16:05:00 -0400 https://www.opko.com/investors/news-events/press-releases/detail/549/opko-health-reports-second-quarter-2026-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/548/opko-health-to-report-second-quarter-2026-financial-results-on-july-27-2026 Thu, 23 Jul 26 12:30:00 -0400 https://www.opko.com/investors/news-events/press-releases/detail/548/opko-health-to-report-second-quarter-2026-financial-results-on-july-27-2026 https://www.opko.com/investors/news-events/press-releases/detail/547/preclinical-data-for-opko-biologics-opk8801001-in-acromegaly-presented-at-endo-2026 Mon, 15 Jun 26 08:00:00 -0400 https://www.opko.com/investors/news-events/press-releases/detail/547/preclinical-data-for-opko-biologics-opk8801001-in-acromegaly-presented-at-endo-2026 https://www.opko.com/investors/news-events/press-releases/detail/546/opko-healths-modex-therapeutics-will-present-data-demonstrating-in-vivo-car-t-cell-generation-and-deep-b-cell-depletion-in-preclinical-studies Tue, 12 May 26 08:00:00 -0400 https://www.opko.com/investors/news-events/press-releases/detail/546/opko-healths-modex-therapeutics-will-present-data-demonstrating-in-vivo-car-t-cell-generation-and-deep-b-cell-depletion-in-preclinical-studies